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IRRITABLE BOWEL SYNDROME (IBS)
SIGNIFICANTLY AFFECTS PATIENT QUALITY
OF LIFE (QOL) AND IS RESPONSIBLE FOR HIGH
COSTS IN FRANCE:THE ENCOLI STUDY
Brun-Strang C1, Lafuma A2, Dapoigny M3,Wainsten JP4
1Novartis-Pharma, Rueil-Malmaison, France; 2CEMKA-EVAL,
Bourg La Reine, France; 3Hotel Dieu, Clermont-Ferrand,
France; 4Université Paris XII, Paris, France
OBJECTIVE: To describe the manage care in patients
presenting IBS and to evaluate, according to the severity
of the disease, the impact of the pathology in terms 
of quality of life (QOL) and resources used (RU).
METHODS: This is a 3-month transversal study of IBS
patients with a retrospective collection of information
covering the previous year. Socio-demographic character-
istics, clinical proﬁle, digestive symptoms, and treat-
ment information were collected. Patients were classiﬁed
according to the Rome I, II, and Mannings criteria.
Patients completed questionnaires to describe their level
of pain and discomfort (SGA), their RU (hospitalisations,
consultations, medications, tests), and work loss over the
last year. A generic QoL questionnaire, the Short Form
36 (SF-36), and a disease-speciﬁc QoL questionnaire (IBS-
QOL) were administered as well as a validated anxiety
and depression scale (HAD). A descriptive comparison of
groups of patients responding to the different IBS classi-
ﬁcation criteria was performed. IBS-related costs during
the previous one-year period were estimated, following a
societal perspective. RESULTS: Of the 445 patients who
had completed all questionnaires, there were 76% of
females; the mean age of the population was 54 ± 15
years. IBS patients had a markedly lower QoL than the
French general population. Nearly 23% of the patients
diagnosed with IBS did not meet any of currently accepted
diagnosis criteria, wheras 38% met all of the diagnostic
classiﬁcation critera. About 10% of IBS patients were
hospitalized for their IBS during the past year. The total
annual direct cost per patient was €773. CONCLU-
SIONS: These results conﬁrm that IBS exacts large direct
medical costs in France and that IBS patients experience
a lower QoL than the general population. Total direct
costs per patient were €773, which is equivalent to
average treatment costs of a French DNID patient 
(diabetic complications excluded).
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HEALTH STATE UTILITIES AND WILLINGNESS
TO PAY IN GERD PATIENTS WITH HEARTBURN
Kartman B
AstraZeneca R&D Mölndal, Mölndal, Sweden
OBJECTIVES: To estimate health state utilities and will-
ingness to pay (WTP) for symptom relief in patients with
gastroesophageal reﬂux disease (GERD), and to examine
the impact of frequency and severity of heartburn on 
utilities and WTP. METHODS: Five hundred four
Swedish GERD patients with heartburn as the predomi-
nant symptom were recruited by physicians. Data on 
utilities, WTP, annual number of days with heartburn
(frequency) and severity of heartburn (mild, moderate,
severe) were collected. Utilities were assessed using the
EuroQol and rating scale (RS). Another RS was used to
assess the utility as patients thought it would be without
heartburn. Annual WTP was assessed for a 25% and
50% reduction in frequency, using a binary question (BQ-
WTP) and a bidding game (BG-WTP). Linear regression
analysis was used to examine the impact of symptoms on
utilities and WTP, and to predict quality adjusted 
life-years (QALYs) gained from reduced symptoms.
RESULTS: Average RS and EuroQol utilities were 0.72
and 0.69. Average RS utility as it would be without heart-
burn was 0.85. Frequency and severity had a signiﬁcant
and negative impact on utilities. RS (EuroQol) utilities by
severity were 0.78, 0.70, 0.62 (0.78, 0.67, 0.51). Average
annual BQ-WTP for the 25% (50%) reduction was 6200
(8200) Swedish kronor. Average annual BQ-WTP for the
25% (50%) reduction was 5100 (6300). Frequency and
severity had a signiﬁcant and positive impact on WTP.
Implied BQ-WTP (BG WTP) per symptom free day
gained was 119 (95). Implied BQ-WTP (BG-WTP) 
per QALY gained was 328000 (263000) based on the
EuroQol and 661000 (530000) based on the RS. CON-
CLUSIONS: The signiﬁcant impact of heartburn on util-
ities and WTP support the validity of the utility and WTP
estimates. The results indicate that GERD patients with
heartburn assign their health states substantial disutility
and are willing to pay considerable amounts for symptom
relief.
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CORRELATION BETWEEN DIFFERENT
PRODUCTIVITY VARIABLES OBTAINED FROM
THE WPAI-GERD QUESTIONNAIRE
Wahlqvist P, Carlsson J
AstraZeneca R&D Mölndal, Mölndal, Sweden
A validation analysis of the Work Productivity and Activ-
ity Impairment questionnaire (WPAI) for assessing lost
productivity due to symptoms of gastroesophageal reﬂux
disease (GERD) has previously been reported, based on
results from a cross-sectional study of a Swedish working
population (N = 136) visiting a general practitioner due
to GERD. The construct validity of the WPAI-GERD was
found to be high, and patients with symptoms of GERD
(heartburn) reported an average of 2.5 hours absence
from work (AW), 23% reduced productivity while at
work (PW) and 30% reduced productivity while doing
regular daily activities (PA) during the week preceding the
consultation. OBJECTIVES: To carry out a further vali-
dation analysis of the WPAI-GERD by investigating the
relationship between the different productivity variables
obtained (AW, PW, PA). METHODS: Pearson correlation
coefﬁcients (PCC) between each productivity variable
were calculated based on results from the original study
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population (including 27 patients without heartburn
symptoms). Correlations were also assessed for each 
category of symptom severity in patients with heart-
burn (mild, n = 30; moderate, n = 64; severe, n = 15).
RESULTS: The correlation between PW and PA was
found to be high and statistically signiﬁcant (PCC 0.82,
p < 0.0001). This ﬁnding was consistent in patients with
either mild, moderate or severe heartburn. A positive rela-
tionship was also found between AW and PW (PCC 0.57,
p < 0.0001), as well as between AW and PA (PCC 0.52,
p < 0.0001). The PCC between AW and PW increased
with heartburn severity (mild: -0.19, moderate: 0.48,
severe: 0.78), since the proportion of patients reporting
any absence from work increased with heartburn sever-
ity (mild: 7%, moderate: 28%, severe: 33%). Thus,
results indicate that in patients with moderate or severe
heartburn, absence from work is also associated with
reduced productivity while at work. CONCLUSIONS:
Results further support the construct validity of the
WPAI-GERD.
GASTROINTESTINAL DISEASES/DISORDERS—
Healthcare Policy
PGS15
FORMULARY CONVERSION OF PROTON PUMP
INHIBITORS: MONITORING FOR POTENTIAL
DRUG INTERACTION
DeLattre ML, Le GH, Schaefer MG, Morreale A, Plowman B
VA San Diego Healthcare System, San Diego, CA, USA
OBJECTIVES: In 2001, the Veterans Affairs Healthcare
System implemented a proton pump inhibitor (PPI) con-
version to rabeprazole in patients who were previously
on either omeprazole or lansoprazole. An unpublished
study by Humphries and colleagues showed that rabepra-
zole, when taken concomitantly with digoxin, increased
the digoxin trough level by 22%, AUC by 19%, and
Cmax by 29%. Safety during the conversion of patients
already taking digoxin and a PPI chronically was uncer-
tain. Therefore, a medical center observational, nonran-
domized prospective drug utilization evaluation (DUE)
was designed to ensure safety throughout the conversion
process. METHODS: One hundred and twelve patients
were identiﬁed via prescription data base search. Pre- and
post-digoxin levels were drawn to assess for the potential
drug interaction and toxicity associated with the switch
from lansoprazole or omeprazole to rabeprazole. Levels
were scheduled for baseline and 7–10 days following 
conversion to rabeprazole. All patients were converted 
to rabeprazole upon clinic visit through pharmacist 
intervention. Adverse effects were monitored at conver-
sion and during follow-up visit. RESULTS: Forty-seven
patients completed the DUE conversion project. Mean
pre-and post-digoxin levels were 0.85 ± 0.93ng/ml and
0.86 ± 0.51ng/ml, respectively (p = 0.93). Twelve patients
had digoxin levels elevated more than 15%, 3 of whom
were symptomatic. CONCLUSIONS: A statistically sig-
niﬁcant drug interaction was not observed. However, due
to absence of a control group in this DUE, we recommend
baseline digoxin levels and patient education of potential
signs and symptoms of digoxin toxicity to ensure safety
during a medication conversion. It does not appear 
that post-conversion digoxin levels are warranted unless
accompanied by signs and symptoms of toxicity.
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EVALUATION OF THE USE OF PROTON PUMP
INHIBITORS IN A PUBLIC HOSPITAL IN 
HONG KONG
Lee VW1,Yick PK2,Yung G1,Tam KY1
1The Chinese University of Hong Kong, Shatin, Hong Kong;
2Pamela Youde Nethersole Eastern Hospital, Hong Kong
OBJECTIVES: Proton pump inhibitors (PPIs) are potent
gastric acid suppressants. They have been widely 
prescribed for various acid-related disorders. In 2000/01,
omeprazole and lansoprazole were PPIs available in the
Pamela Youde Nethersole Eastern Hospital (PYNEH) and
the consumption of PPIs accounted for HK$3.4 millions
(US$1 = HK$7.8), which was 3% of the total drug expen-
diture of the hospital. A drug utilization evaluation of
PPIs was carried out to estimate the impact of unlicensed
uses of PPIs on the overall drug expenditure in this local
public hospital. METHOD: A retrospective study was
performed on patients admitted to the PYNEH. The study
cohort consisted of all inpatients (excluding intensive care
patients) and outpatients who were aged 18-year old or
above and were dispensed PPIs for seven days or more
(except for those on intravenous route PPIs) between 1
January and 30 June 2001. Two hundred and four patient
medical charts were randomly selected from the cohort.
Clinical and laboratory data were collected from the
medical records. RESULTS: After reviewing 204 patient
records, 185 (90.7%) prescriptions of PPIs were complied
with the licensed indications. Of the 19 prescriptions of
unlicensed uses, 9 (47.4%) and 4 (21.1%) prescriptions
were for treatment of gastritis and/or duodenitis and 
for empirical treatment of epigastric pain respectively.
The drug cost-avoidance of unlicensed uses of PPI was
HK$19,477.6. Data collected during this 6-month period
were extrapolated to one year, the projected annual pos-
sible cost-avoidance of unlicensed uses would be approx-
imately HK$400,000 which accounts for 0.35% of the
total drug expenditure. CONCLUSION: This study con-
cluded that the compliance rate of licensed indications of
PPIs was high but the unlicensed uses still resulted in a
signiﬁcant drug cost-avoidance. Educational programs
may be designed to reduce the incidence of unlicensed
uses and thus to reduce the associated costs in the future.
